Sunday, April 11, 2021 11:13:49 AM
The SAP and the endpoints the analyses will use when data is unblinded will be the revised reordered SAP and endpoints therewithin, ie, the primary endpoint is
"The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses"
and the first secondary endpoint is
"The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from
comparable, contemporaneous clinical trials, in patients with recurrent GBM."
Source: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB
As we all know, part of the reason for revising SAP (endpoints are part of it) is pseudo-progression wreaking havoc on "original" primary PFS endpoint and cross-over confoundment on "original" secondary endpoint OS."
Nonetheless, sponsors of trials may revise respective SAPs while they remain blinded according to FDA guideline, and it's exactly that NWBio revised its SAP while remained blinded. NWBio would be (has been) for the first time using this SAP to analyze unblinded data.
After all, since well more than five years have passed after the last patient in the trial was enrolled and treated, any data/analyses on PFS will be truly secondary, which may be used as an evidence support. The focus is now and should be now squarely on OS, in particular long-term survival.
It should be stressed NWBio revising SAP and endpoints are conducted to have more accurate and up-to-date metrics used to measure efficacy of the trial data, not to make up for "a failed trial" so it is not only necessary but essential.
One other reason for revising SAP is obviously as of today it is understood any immuno-therapeutic trials must be conducted longer enough to fully capture the effectiveness of the underlying immuno-therapeutic agents/vaccines due to normally delayed effects. For this reason, long-term OS is most important relative to the median OS, or the now obsolete surrogate endpoints such as PFS. Not only has NWBio exactly done that but it has acquired unprecedent rich and extensive data for all patients in the trial.
With Dr. Liau's presentation slides, particular those comparable, contemporaneous prior trial curves as well as the blinded data of Phase 3 DCVax-L trial as of 2017 (published in 2018) and its subsequent update data in 2018, plus the information arm data presented, it should be no difficult to conclude both the primary endpoint and the first secondary endpoint will be significant when analyses of unblinded data are announced in the near future.
GL
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM